Why Sarepta Didn't Start a Big DMD Trial Quicker

If the Food and Drug Administration approves Sarepta Therapeutics' Duchenne muscular dystrophy this month, many will complain that the Cambridge biotech got away with a drug approval without having done the work needed to prove it really works.

But that viewpoint overlooks at least two big factors that kept the company from being able to start a trial any faster than it did.

Comments from FDA officials last week suggest that Sarepta (Nasdaq: SRPT) is to blame for not starting a large, placebo-controlled trial earlier than it did.

Back to news